Equity intelligence report • May 31, 2026
Novo Nordisk has achieved a significant 32% increase in first-quarter sales to $15.17 billion but faces mounting legal challenges, including a lawsuit against partner Hims. As the company navigates competitive pressures in the obesity drug market, it has lowered its 2026 sales outlook by 4% to 12%. While Novo Nordisk is responding to this dynamic by cutting insulin prices by up to 75% and reducing Wegovy prices in China by up to 48%, its stock remains volatile amid a broader decline of over 40% in the past year. The company is attempting to bolster its market position amidst intensifying competition and investor scrutiny.
Click a month on the chart to update the report below.
